Dopamine- or L-DOPA-induced neurotoxicity: The role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease
暂无分享,去创建一个
[1] E. Cadenas,et al. Effect of superoxide dismutase on the autoxidation of various hydroquinones--a possible role of superoxide dismutase as a superoxide:semiquinone oxidoreductase. , 1988, Free radical biology & medicine.
[2] C. Welch,et al. Human Class Mu Glutathione Transferases, in Particular Isoenzyme M2-2, Catalyze Detoxication of the Dopamine Metabolite Aminochrome* , 1997, The Journal of Biological Chemistry.
[3] J. Bermak,et al. Evidence for non‐oxidative dopamine cytotoxicity: potent activation of NF‐κ B and lack of protection by anti‐oxidants , 2001, Journal of neurochemistry.
[4] D. Metodiewa,et al. Reactive oxygen species and reactive nitrogen species: Relevance to cyto(neuro)toxic events and neurologic disorders. An overview , 1999, Neurotoxicity Research.
[5] L. Greene,et al. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[6] M. Asanuma,et al. Scavenging Effects of Dopamine Agonists on Nitric Oxide Radicals , 1996, Journal of neurochemistry.
[7] Alberto Gatti,et al. The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease , 2002, FEBS letters.
[8] S. Fujisawa,et al. Induction of apoptosis by dopamine in human oral tumor cell lines. , 2000, Anticancer research.
[9] J. Smythies. The neurotoxicity of glutamate, dopamine, iron and reactive oxygen species: Functional interrelationships in health and disease: A review — discussion , 1999, Neurotoxicity Research.
[10] T. Sarna,et al. Tyrosinase-catalyzed oxidation of dopa and related catechol(amine)s: a kinetic electron spin resonance investigation using spin-stabilization and spin label oximetry. , 1987, Biochimica et biophysica acta.
[11] Peter T. Lansbury,et al. Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.
[12] J. Segura-Aguilar,et al. On the mechanism of the Mn3(+)-induced neurotoxicity of dopamine:prevention of quinone-derived oxygen toxicity by DT diaphorase and superoxide dismutase. , 1989, Chemico-biological interactions.
[13] M. LaVoie,et al. Dopamine Quinone Formation and Protein Modification Associated with the Striatal Neurotoxicity of Methamphetamine: Evidence against a Role for Extracellular Dopamine , 1999, The Journal of Neuroscience.
[14] P. Riederer,et al. Iron‐Melanin Interaction and Lipid Peroxidation: Implications for Parkinson's Disease , 1991, Journal of neurochemistry.
[15] MoonHee Lee,et al. Effect of the overexpression of wild‐type or mutant α‐synuclein on cell susceptibility to insult , 2001 .
[16] A. Björklund,et al. Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System , 2002, The Journal of Neuroscience.
[17] K. Wakamatsu,et al. Cysteinyldopamine is not incorporated into neuromelanin , 1991, Neuroscience Letters.
[18] C. Carter,et al. Aspirin and Salicylate Protect Against MPTP‐Induced Dopamine Depletion in Mice , 1998, Journal of neurochemistry.
[19] M. Zigmond,et al. Modification of Dopamine Transporter Function: Effect of Reactive Oxygen Species and Dopamine , 1996, Journal of neurochemistry.
[20] H. M. Geller,et al. l‐DOPA Cytotoxicity to PC12 Cells in Culture Is via Its Autoxidation , 1995, Journal of neurochemistry.
[21] R. Kostrzewa. Selective neurotoxins, chemical tools to probe the mind: The first Thirty years and beyond , 1999, Neurotoxicity Research.
[22] K. Vrana,et al. Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase , 1998, Journal of neuroscience research.
[23] J. Townsend,et al. Pre- and Postsynaptic Neurotoxic Effects of Dopamine Demonstrated by Intrastriatal Injection , 1993, Experimental Neurology.
[24] Barry Halliwell,et al. Reactive Oxygen Species and the Central Nervous System , 1992, Journal of neurochemistry.
[25] A. Aguzzi,et al. Tyrosinase is a new marker for cell populations in the mouse neural tube. , 1995, Developmental dynamics : an official publication of the American Association of Anatomists.
[26] L. Elferink,et al. Tyrosine Hydroxylase Is Inactivated by Catechol‐Quinones and Converted to a Redox‐Cycling Quinoprotein , 1999, Journal of neurochemistry.
[27] R. Coccia,et al. Catecholamines oxidation by xanthine oxidase. , 1997, Biochimica et biophysica acta.
[28] H. M. Swartz,et al. Total and paramagnetic metals in human substantia nigra and its neuromelanin , 1993, Journal of neural transmission. Parkinson's disease and dementia section.
[29] D. Tse,et al. Potential oxidative pathways of brain catecholamines. , 1976, Journal of medicinal chemistry.
[30] L. Chia,et al. Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease , 2005, Journal of Neural Transmission.
[31] A. Carlsson,et al. Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species , 1986, Neuropharmacology.
[32] P. Lansbury,et al. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. , 2001, Biochemistry.
[33] W. Damerau,et al. Protection of melanoma cells against superoxide radicals by melanins , 2004, Journal of Cancer Research and Clinical Oncology.
[34] The Pathogenesis of Parkinson's Disease. , 1963, Canadian Medical Association journal.
[35] A. Korczyn. Drug treatment of Parkinson's disease , 2004, Dialogues in clinical neuroscience.
[36] G. Dryhurst,et al. Irreversible Inhibition of Mitochondrial Complex I by 7‐(2‐Aminoethyl)‐3,4‐Dihydro‐5‐Hydroxy‐2H‐1,4‐Benzothiazine‐3‐Carboxylic Acid (DHBT‐1): A Putative Nigral Endotoxin of Relevance to Parkinson's Disease , 1997, Journal of neurochemistry.
[37] M. Asanuma,et al. The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals , 2002, Neuroscience Research.
[38] M. Kohno,et al. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro , 1994, Brain Research.
[39] S. Ito,et al. Does tyrosinase exist in neuromelanin-pigmented neurons in the human substantia nigra? , 1998, Neuroscience Letters.
[40] K. Marcelain,et al. Copper neurotoxicity is dependent on dopamine‐mediated copper uptake and one‐electron reduction of aminochrome in a rat substantia nigra neuronal cell line , 2001, Journal of neurochemistry.
[41] Y. Agid,et al. Is the Vulnerability of Neurons in the Substantia Nigra of Patients with Parkinson's Disease Related to Their Neuromelanin Content? , 1992, Journal of neurochemistry.
[42] F Beermann,et al. New evidence for presence of tyrosinase in substantia nigra, forebrain and midbrain. , 1998, Brain research. Molecular brain research.
[43] J. Um,et al. Antiapoptotic role of NF‐κB in the auto‐oxidized dopamine‐induced apoptosis of PC12 cells , 2001, Journal of neurochemistry.
[44] A H Stokes,et al. Tyrosinase mRNA is expressed in human substantia nigra. , 1997, Brain research. Molecular brain research.
[45] T. Sarna,et al. The effect of melanin on iron associated decomposition of hydrogen peroxide. , 1988, Free radical biology & medicine.
[46] C. Mytilineou,et al. Toxic and Protective Effects of l‐DOPA on Mesencephalic Cell Cultures , 1993, Journal of neurochemistry.
[47] R. Kostrzewa,et al. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease , 2002, Amino Acids.
[48] D. Sulzer,et al. Intraneuronal dopamine-quinone synthesis: A review , 1999, Neurotoxicity Research.
[49] M. Asanuma,et al. Inhibition of Tyrosinase Reduces Cell Viability in Catecholaminergic Neuronal Cells , 2000, Journal of neurochemistry.
[50] M. Miranda,et al. Harding-passey mouse-melanoma tyrosinase inactivation by reaction products and activation by L-epinephrine. , 1983, General pharmacology.
[51] T. Sarna,et al. Antioxidant action of neuromelanin: the mechanism of inhibitory effect on lipid peroxidation. , 1995, Archives of biochemistry and biophysics.
[52] K. Mizukawa,et al. Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa. , 1993, Advances in neurology.
[53] T. Sarna,et al. The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. , 1995, Biochimica et biophysica acta.
[54] Sarah J. Tabrizi,et al. Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity , 2000 .
[55] Mitsutoshi Yamamoto,et al. Differential effects of chronic l-DOPA treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine , 1994, Neuroscience Letters.
[56] M. Asanuma,et al. Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. , 2003, Biochimica et biophysica acta.
[57] D. Dexter,et al. Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease. , 1996, Free radical research.
[58] I. Ziv,et al. Prevention of Dopamine-Induced Cell Death by Thiol Antioxidants: Possible Implications for Treatment of Parkinson's Disease , 1996, Experimental Neurology.
[59] C. Welch,et al. Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects. , 1998, Biochimica et biophysica acta.
[60] M. Zigmond,et al. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[61] D. Jacobowitz,et al. Pharmacological actions of 6-hydroxydopamine. , 1974, Pharmacological reviews.
[62] V. Hearing,et al. Mammalian tyrosinase. A comparison of tyrosine hydroxylation and melanin formation. , 1976, The Biochemical journal.
[63] W. Freed,et al. Bromocriptine Protects Dopaminergic Neurons from Levodopa-Induced Toxicity by Stimulating D2Receptors , 1999, Experimental Neurology.
[64] R. Kostrzewa,et al. Dopaminergic denervation enhances susceptibility to hydroxyl radicals in rat neostriatum , 2000, Amino Acids.
[65] Fujita Keisuke,et al. Conjugation of dopa and 5-S-cysteinyldopa with cysteine mediated by superoxide radical. , 1982 .
[66] D. Casper,et al. Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro , 2000, Neuroscience Letters.
[67] L. Mosca,et al. Lipoxygenase-catalyzed oxidation of catecholamines. , 1994, Biochemical and biophysical research communications.
[68] M. Asanuma,et al. Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain , 1998, Brain Research.
[69] I. Kanazawa,et al. Repeated l-DOPA administration reduces the ability of dopamine storage and abolishes the supersensitivity of dopamine receptors in the striatum of intact rat , 1993, Neuroscience Research.
[70] M. Asanuma,et al. Bromocriptine Markedly Suppresses Levodopa-Induced Abnormal Increase of Dopamine Turnover in the Parkinsonian Striatum , 2000, Neurochemical Research.
[71] K. Lange,et al. Pathogenesis of Parkinson's disease. , 1992, Current opinion in neurology and neurosurgery.
[72] U. Ungerstedt,et al. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. , 1968, European journal of pharmacology.
[73] S. Berman,et al. Dopamine Oxidation Alters Mitochondrial Respiration and Induces Permeability Transition in Brain Mitochondria , 1999, Journal of neurochemistry.
[74] M. Kohno,et al. Neuroprotective effects of non‐steroidal anti‐inflammatory drugs by direct scavenging of nitric oxide radicals , 2001, Journal of neurochemistry.
[75] F. Amicarelli,et al. Liposome-entrapped tyrosinase: a tool to investigate the regulation of the Raper-Mason pathway. , 1988, Biochimica et biophysica acta.
[76] B. Ferger,et al. Inhibition of the cyclooxygenase isoenzymes COX‐1 and COX‐2 provide neuroprotection in the MPTP‐mouse model of Parkinson's disease , 2001, Synapse.
[77] D. Radice,et al. Iron and Other Metals in Neuromelanin, Substantia Nigra, and Putamen of Human Brain , 1994, Journal of neurochemistry.
[78] Pico Caroni,et al. Neuropathology in Mice Expressing Human α-Synuclein , 2000, The Journal of Neuroscience.
[79] C. Rice-Evans,et al. Inhibition of Peroxynitrite‐Mediated Oxidation of Dopamine by Flavonoid and Phenolic Antioxidants and Their Structural Relationships , 1999, Journal of neurochemistry.
[80] John Hardy,et al. The A53T α-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity , 2000, The Journal of Neuroscience.
[81] M. LaVoie,et al. Peroxynitrite‐ and Nitrite‐Induced Oxidation of Dopamine : Implications for Nitric Oxide in Dopaminergic Cell Loss , 1999, Journal of neurochemistry.
[82] K. Fujita,et al. Conjugation of dopa and 5-S-cysteinyldopa with cysteine mediated by superoxide radical. , 1982, Biochemical pharmacology.
[83] D. Graham. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. , 1978, Molecular pharmacology.
[84] P. Lansbury,et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[85] S. Fahn,et al. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity , 1993, Annals of neurology.
[86] N. Ogawa,et al. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist , 1999, Brain Research.
[87] A. Lees,et al. Conjugates of Catecholamines with Cysteine and GSH in Parkinson's Disease: Possible Mechanisms of Formation Involving Reactive Oxygen Species , 1998, Journal of neurochemistry.
[88] Story C. Landis,et al. Catecholamine Synthesis is Mediated by Tyrosinase in the Absence of Tyrosine Hydroxylase , 1999, The Journal of Neuroscience.
[89] J. Segura-Aguilar,et al. Behavioral effects of aminochrome and dopachrome injected in the rat substantia nigra , 2002, Pharmacology Biochemistry and Behavior.
[90] B. Mannervik,et al. Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. , 1997, The Biochemical journal.
[91] M. Kawai,et al. Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain. , 1995, Archives internationales de pharmacodynamie et de therapie.
[92] J. Segura-Aguilar,et al. Superoxide dismutase and catalase enhance autoxidation during one-electron reduction of aminochrome by NADPH-cytochrome P-450 reductase. , 1995, Biochemical and molecular medicine.
[93] V. Hearing,et al. Neurotoxicity due to o-Quinones: Neuromelanin formation and possible mechanisms for o-Quinone detoxification , 1999, Neurotoxicity Research.
[94] S. Hirai,et al. Inhibitory effects of bromocriptine on phospholipid peroxidation induced by DOPA and iron , 1995, Neuroscience Letters.
[95] M. Mena,et al. l‐DOPA Inhibits Complex IV of the Electron Transport Chain in Catecholamine‐Rich Human Neuroblastoma NB69 Cells , 1995, Journal of neurochemistry.
[96] H. M. Swartz,et al. Interaction of neuromelanin and iron in substantia nigra and other areas of human brain , 1996, Neuroscience.
[97] R. Strong,et al. Prostaglandin H Synthetase‐Mediated Metabolism of Dopamine: Implication for Parkinson's Disease , 1995, Journal of neurochemistry.
[98] G. Cohen,et al. 6-Hydroxydopamine: Evidence for Superoxide Radical as an Oxidative Intermediate , 1973, Science.
[99] M. Hahne,et al. Tyrosinase, the key enzyme in melanin synthesis, is expressed in murine brain. , 1996, European journal of biochemistry.
[100] M. Mena,et al. Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants , 1995, Brain Research.
[101] J. Cadet,et al. Long-term behavioral and biochemical effects of 6-hydroxydopamine injections in rat caudate-putamen , 1991, Brain Research Bulletin.
[102] S Fahn,et al. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. , 1999, Archives of neurology.
[103] J. Trojanowski,et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.
[104] M. Colado,et al. Studies on the role of dopamine in the degeneration of 5‐HT nerve endings in the brain of Dark Agouti rats following 3,4‐methylenedioxymethamphetamine (MDMA or ‘ecstasy’) administration , 1999, British journal of pharmacology.
[105] A. Bonfigli,et al. Tyrosinase-like activity in normal human substantia nigra. , 1984, General pharmacology.
[106] G. Cohen,et al. The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. , 1974, The Journal of biological chemistry.
[107] P. Riederer,et al. Structural Characteristics of Human Substantia Nigra Neuromelanin and Synthetic Dopamine Melanins , 2000, Journal of neurochemistry.
[108] W. H. Oertel,et al. Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.
[109] M. Schultzberg,et al. Distribution of dt diaphorase in the rat brain: Biochemical and immunohistochemical studies , 1988, Neuroscience.
[110] F. Beermann,et al. Regulation of the tyrosinase promoter in transgenic mice: expression of a tyrosinase-lacZ fusion gene in embryonic and adult brain. , 1997, Pigment cell research.
[111] C. Waters,et al. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. , 1995, The Journal of clinical investigation.
[112] T. Hastings. Enzymatic Oxidation of Dopamine: The Role of Prostaglandin H Synthase , 1995, Journal of neurochemistry.
[113] F. L. Muiswinkel,et al. Drug treatment of parkinson's disease : Time for phase II , 2000 .
[114] Bruce A. Yankner,et al. Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.